Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Abstract Purpose The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this assay detects most PIK3CA mu...

Full description

Bibliographic Details
Main Authors: Olga Martínez-Sáez, Nuria Chic, Tomás Pascual, Barbara Adamo, Maria Vidal, Blanca González-Farré, Esther Sanfeliu, Francesco Schettini, Benedetta Conte, Fara Brasó-Maristany, Adela Rodríguez, Débora Martínez, Patricia Galván, Ana Belén Rodríguez, Antonio Martinez, Montserrat Muñoz, Aleix Prat
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Breast Cancer Research
Subjects:
Breast cancer
PIK3CA
Mutations
Alpelisib
Companion diagnostic
Hotspot mutations
Online Access:http://link.springer.com/article/10.1186/s13058-020-01284-9

Internet

http://link.springer.com/article/10.1186/s13058-020-01284-9

Similar Items